Kindred Biosciences Inc (NASDAQ:KIN) has been assigned an average recommendation of “Buy” from the nine brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $8.88.

A number of analysts recently weighed in on KIN shares. Aegis restated a “buy” rating on shares of Kindred Biosciences in a research note on Tuesday, June 2nd. Stifel Nicolaus decreased their price target on Kindred Biosciences from $14.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, March 17th. BidaskClub downgraded Kindred Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, March 18th. Zacks Investment Research upgraded Kindred Biosciences from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a research note on Saturday, May 30th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Kindred Biosciences in a research note on Tuesday, March 17th.

NASDAQ:KIN traded up $0.23 during mid-day trading on Tuesday, reaching $4.49. 501,883 shares of the stock were exchanged, compared to its average volume of 308,638. The company has a 50 day simple moving average of $4.60 and a 200-day simple moving average of $6.71. The stock has a market capitalization of $162.27 million, a P/E ratio of -2.58 and a beta of 1.00. The company has a quick ratio of 5.65, a current ratio of 5.73 and a debt-to-equity ratio of 0.36. Kindred Biosciences has a 1 year low of $3.11 and a 1 year high of $11.93.

Kindred Biosciences (NASDAQ:KIN) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.04). Kindred Biosciences had a negative net margin of 1,567.56% and a negative return on equity of 72.77%. The company had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $1.75 million. As a group, research analysts predict that Kindred Biosciences will post -1.27 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KIN. Citigroup Inc. grew its position in shares of Kindred Biosciences by 38.3% in the first quarter. Citigroup Inc. now owns 11,282 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 3,123 shares during the period. BNP Paribas Arbitrage SA grew its position in shares of Kindred Biosciences by 123.7% in the first quarter. BNP Paribas Arbitrage SA now owns 11,404 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 6,306 shares during the period. Marshall Wace LLP purchased a new stake in shares of Kindred Biosciences in the first quarter valued at $53,000. Bank of Montreal Can grew its position in shares of Kindred Biosciences by 99.5% in the fourth quarter. Bank of Montreal Can now owns 6,474 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 3,229 shares during the period. Finally, Marshall Wace North America L.P. purchased a new stake in shares of Kindred Biosciences in the fourth quarter valued at $59,000. 66.90% of the stock is owned by institutional investors.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Featured Article: Quiet Period

Analyst Recommendations for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.